Aomori T, Tsuchiya A, Suzuki S, Jibiki A, Otsuka N, Ishioka E, Kaneko Y, Takeuchi T, Nakamura T
Pharmazie. 2017 Feb 1;72(2):95-97. doi: 10.1691/ph.2017.6791.
In rheumatoid arthritis (RA) treatment, the concomitant use of methotrexate has been shown to reduce the incidence of antibodies to infliximab (ATI), on the other hand, it is unclear whether azathioprine can reduce ATI production. We enrolled a total of 10 Japanese adult patients with RA who were treated with infliximab concomitantly with methotrexate or azathioprine. Serum concentrations of infliximab and ATI of these patients were measured. The mean serum infliximab concentrations was 1.6±1.3 μg/ml in patients with methotrexate and 1.0±0.5 μg/ml in patients with azathioprine. Serum ATI concentrations were below the limit of quantitation in 4 of 5 patients in each group. The results from the present study suggest that azathioprine suppresses ATI production.
在类风湿性关节炎（RA）治疗中，已表明甲氨蝶呤的联合使用可降低抗英夫利昔单抗抗体（ATI）的发生率，另一方面，硫唑嘌呤是否能降低ATI的产生尚不清楚。我们共纳入了10名接受英夫利昔单抗联合甲氨蝶呤或硫唑嘌呤治疗的日本成年RA患者。测量了这些患者的英夫利昔单抗和ATI的血清浓度。甲氨蝶呤组患者的平均血清英夫利昔单抗浓度为1.6±1.3μg/ml，硫唑嘌呤组患者为1.0±0.5μg/ml。每组5名患者中有4名患者的血清ATI浓度低于定量限。本研究结果表明硫唑嘌呤可抑制ATI的产生。
